Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data
Portfolio Pulse from Vandana Singh
eFFECTOR Therapeutics Inc (EFTR) announced disappointing results from the Phase 2 KICKSTART trial of tomivosertib in combination with Merck & Co Inc's (MRK) Keytruda for non-small cell lung cancer, failing to meet the primary endpoint. The company will discontinue the development of tomivosertib for this indication but plans to focus on developing Zotatifin for breast cancer and continue a trial of tomivosertib in AML. EFTR shares dropped 78.1% to $3.6.
April 04, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Merck & Co Inc's Keytruda was part of the combination treatment in eFFECTOR's failed trial, but the impact on MRK is likely minimal given its diverse portfolio.
Although Merck's Keytruda was used in combination with eFFECTOR's tomivosertib in the failed trial, Merck's broad product portfolio and the drug's established market presence likely mitigate any negative impact from this specific trial's outcome.
CONFIDENCE 80
IMPORTANCE 20
RELEVANCE 30
NEGATIVE IMPACT
eFFECTOR Therapeutics announced halting development of lung cancer drug tomivosertib after failing to meet trial endpoints, causing a 78.1% drop in shares.
The discontinuation of tomivosertib's development for lung cancer due to disappointing trial results directly impacts EFTR's stock, as evidenced by the significant drop in share price. This development is likely to negatively affect investor confidence in the short term.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100